Effects of manidipine and delapril in hypertensive patients with type 2 diabetes mellitus: The delapril and manidipine for nephroprotection in diabetes (DEMAND) randomized clinical trial

Hypertension

Volumn 58, Issue 5, 2011, Pages 776-783

  Ruggenenti, Piero ^a,b   Lauria, Giuseppe ^c   Iliev, Ilian Petrov ^a   Fassi, Anna ^a   Ilieva, Aneliya Parvanova ^a   Rota, Stefano ^a,b   Chiurchiu, Carlos ^a   Barlovic, Drazenka Pongrac ^d   Sghirlanzoni, Angelo ^c   Lombardi, Raffaella ^c   Penza, Paola ^c   Cavaletti, Guido ^e   Piatti, Maria Luisa ^f   Frigeni, Barbara ^f   Filipponi, Marco ^b   Rubis, Nadia ^a   Noris, Greta ^a   Motterlini, Nicola ^a   Ene Iordache, Bogdan ^a   Gaspari, Flavio ^a   Perna, Annalisa ^a   Zaletel, Jelka ^d   Bossi, Antonio ^g   Dodesini, Alessandro Roberto ^b   Trevisan, Roberto ^b   Remuzzi, Giuseppe ^a,b   more..

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b OSPEDALI RIUNITI   (Italy)

^c DEPARTMENT OF NEUROSURGERY   (Italy)

^d UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^e UNIVERSITY OF MILANO BICOCCA   (Italy)

^f SAN GERARDO HOSPITAL   (Italy)

^g Treviglio Hospital   (Italy)

Author keywords

ACE inhibitors; Calcium channel blockers; Cardiovascular complications; Diabetic nephropathy; Diabetic neuropathy; Diabetic retinopathy; Manidipine

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLONIDINE; DELAPRIL; DOXAZOSIN; FUROSEMIDE; HYDROCHLOROTHIAZIDE; INDAPAMIDE; MANIDIPINE; METHYLDOPA; PLACEBO; PRAZOSIN;

ADULT; ALBUMINURIA; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG TOLERABILITY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; METABOLIC REGULATION; MULTICENTER STUDY; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETINOPATHY; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD GLUCOSE; BODY MASS INDEX; CALCIUM CHANNEL BLOCKERS; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DIHYDROPYRIDINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERTENSION; INDANS; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; PROGNOSIS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 83155180436     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.111.174474     Document Type: Article

References (27)

1. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE Study and MICRO-HOPE Substudy. Lancet. 2000;355:253-259.
2. Ruggenenti P, Fassi A, Ilieva AP, Bruno S, Iliev IP, Brusegan V, Rubis N, Gherardi G, Arnoldi F, Ganeva M, Ene-Iordache B, Gaspari F, Perna A, Bossi A, Trevisan R, Dodesini AR, Remuzzi G. Preventing microal-buminuria in type 2 diabetes. N Engl J Med. 2004;351:1941-1951.
3. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephrop-athy in patients with type 2 diabetes. N Engl J Med. 2001;345:870-878.
4. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861-869.
5. Sjolie AK, Klein R, Porta M, Orchard T, Fuller J, Parving HH, Bilous R, Chaturvedi N. Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial. Lancet. 2008;372:1385-1393.
6. Coppey LJ, Davidson EP, Rinehart TW, Gellett JS, Oltman CL, Lund DD, Yorek MA. ACE inhibitor or angiotensin II receptor antagonist attenuates diabetic neuropathy in streptozotocin-induced diabetic rats. Diabetes. 2006;55:341-348. (Pubitemid 43343262)
7. Malik RA, Williamson S, Abbott C, Carrington AL, Iqbal J, Schady W, Boulton AJ. Effect of angiotensin-converting-enzyme (ACE) inhibitor trandolapril on human diabetic neuropathy: randomised double-blind controlled trial. Lancet. 1998;352:1978-1981. (Pubitemid 29000865)
8. Hayashi K, Ozawa Y, Fujiwara K, Wakino S, Kumagai H, Saruta T. Role of actions of calcium antagonists on efferent arterioles-with special references to glomerular hypertension. Am J Nephrol. 2003;23:229-244. (Pubitemid 36980719)
9. Cavalieri L, Cremonesi G. Metabolic effects of manidipine. Am J Car-diovasc Drugs. 2009;9:163-176.
10. Fogari R, Mugellini A, Zoppi A, Lazzari P, Destro M, Rinaldi A, Preti P. Effect of successful hypertension control by manidipine or lisinopril on albuminuria and left ventricular mass in diabetic hypertensive patients with microalbuminuria. Eur J Clin Pharmacol. 2005;61:483-490. (Pubitemid 41218819)
11. Fogari R, Corradi L, Zoppi A, Lazzari P, Mugellini A, Preti P, Rinaldi A. Addition of manidipine improves the antiproteinuric effect of candesartan in hypertensive patients with type II diabetes and microalbuminuria. Am J Hypertens. 2007;20:1092-1096. (Pubitemid 47446175)
12. Ene-Iordache B, Carminati S, Antiga L, Rubis N, Ruggenenti P, Remuzzi G, Remuzzi A. Developing regulatory-compliant electronic case report forms for clinical trials: experience with the demand trial. J Am Med Inform Assoc. 2009;16:404-408.
13. Cornblath DR, Chaudhry V, Carter K, Lee D, Seysedadr M, Miernicki M, Joh T. Total neuropathy score: validation and reliability study. Neurology. 1999;53:1660-1664. (Pubitemid 29530336)
14. Gaspari F, Perico N, Ruggenenti P, Mosconi L, Amuchastegui CS, Guerini E, Daina E, Remuzzi G. Plasma clearance of nonradioactive iohexol as a measure of glomerular filtration rate. J Am Soc Nephrol. 1995;6:257-263.
15. Parvanova A, Iliev I, Filipponi M, Dimitrov BD, Vedovato M, Tiengo A, Trevisan R, Remuzzi G, Ruggenenti P. Insulin resistance and proliferative retinopathy: a cross-sectional, case-control study in 115 patients with type 2 diabetes. J Clin Endocrinol Metab. 2004;89:4371-4376. (Pubitemid 39244440)
16. Wilkinson CP, Ferris FL III, Klein RE, Lee PP, Agardh CD, Davis M, Dills D, Kampik A, Pararajasegaram R, Verdaguer JT. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology. 2003;110:1677-1682. (Pubitemid 37025422)
17. Lebovitz HE, Wiegmann TB, Cnaan A, Shahinfar S, Sica DA, Broadstone V, Schwartz SL, Mengel MC, Segal R, Versaggi JA, Bolton WK. Renal protective effects of enalapril in hypertensive NIDDM: role of baseline albuminuria. Kidney Int. 1994;45(suppl):S150-S155.
18. Ruggenenti P, Perna A, Gherardi G, Gaspari F, Benini R, Remuzzi G. Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Ne-phropathy. Lancet. 1998;352:1252-1256. (Pubitemid 28470337)
19. Andersen S, Brochner-Mortensen J, Parving HH. Kidney function during and after withdrawal of long-term irbesartan treatment in patients with type 2 diabetes and microalbuminuria. Diabetes Care. 2003;26: 3296-3302. (Pubitemid 37466890)
20. Beck GJ, Berg RL, Coggins CH, Gassman JJ, Hunsicker LG, Schluchter MD, Williams GW. Design and statistical issues of the Modification of Diet in Renal Disease Trial. The Modification of Diet in Renal Disease Study Group. Control Clin Trials. 1991;12:566-586.
21. Lindeman RD, Tobin J, Shock NW. Longitudinal studies on the rate of decline in renal function with age. J Am Geriatr Soc. 1985;33:278-285. (Pubitemid 15087125)
22. Cooper-DeHoff RM, Pacanowski MA, Pepine CJ. Cardiovascular therapies and associated glucose homeostasis: implications across the dysglycemia continuum. J Am Coll Cardiol. 2009;53:S28-S34.
23. Ruggenenti P, Remuzzi G. Time to abandon microalbuminuria? Kidney Int. 2006;70:1214-1222. (Pubitemid 44435172)
24. Mauer M, Zinman B, Gardiner R, Suissa S, Sinaiko A, Strand T, Drummond K, Donnelly S, Goodyer P, Gubler MC, Klein R. Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med. 2009;361:40-51.
25. Ruggenenti P, Remuzzi G. Proteinuria: Is the ONTARGET renal substudy actually off target? Nat Rev Nephrol. 2009;5:436-437.
26. Jamerson K, Weber MA, Bakris GL, Dahlof B, Pitt B, Shi V, Hester A, Gupte J, Gatlin M, Velazquez EJ. Benazepril plus amlodipine or hydro-chlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359:2417-2428.
27. Gu K, Cowie CC, Harris MI. Diabetes and decline in heart disease mortality in US adults. JAMA. 1999;281:1291-1297. (Pubitemid 29174480)